Neurotech initiates Phase 1 clinical trial for AAD-2004

Neurotech Pharmaceuticals said on August 30 that it has begun dosing in the Phase 1 clinical testing of AAD-2004, a potent spin trapping molecule and microsomal prostaglandin E synthase-1 inhibitor, targeting Alzheimer's, Parkinson's, and Lou Gehrig's Disease.

AAD-2004 was developed as a dual function drug to remove free radicals and PGE2, the key mediators of nerve injury in Alzheimer's dis...